Pfizer, Abbott profits increase, but generics damp revenues

Article Abstract:

Soaring profit increases for the first quarter at Pfizer Inc. of the United States were posted at $4.11 billion from $301 million last year. Revenue was due to tax considerations and lower costs. Abbot Laboratories Inc. also of the United States posted first quarter net profit of $865 million, up 3.2 percent from $838 million last year.

Market share, Company market share, ABT, Abbott Laboratories (Abbott Park, Illinois)

---

Schering-Plough swings to profit, aided by cholesterol-drug venture

Article Abstract:

Schering-Plough Corp. of the United States posted $126 million in profit for the fourth quarter with sales up to $2.32 billion. Revenue results were aided by the pharmaceutical companies joint venture with its cholesterol-drug and increased sales of its hepatitis, arthritis and allergy treatments.

Company Profile, Schering-Plough Corp.

---

Pfizer profit fell 30% in quarter; Wyeth and Roche Holding gain

Article Abstract:

Pfizer Inc. of the United States posted a second quarter 30 percent slide in profit to $2.42 billion from $3.46 billion a year earlier. Revenues were buoyed by a large tax break and sales growth, particularly for Lipitor.

Industry overview

Similar abstracts:

• Abstracts: Peugeot's profit falls 83 percent as sales of autos decline. Renault profit falls 25% on costs, weak demand
• Abstracts: Olex plots submarine surprise! Turkish seiners for France. Surface drive helps 'halve fuel costs'
• Abstracts: Merck, Schering-Plough results get boost from cholesterol drugs. Amgen's net income rises 20%; new drugs help Lilly post profit
• Abstracts: Russia's gas diplomacy fuels realignment of former Soviet Bloc. part 2 Russian energy grip splits EU
• Abstracts: Mercedes seeks to reverse damage to its image. Bling-bling Buick: seeking younger buyers, General Motors' staid brand uses customized cars, celebrities to reach the hip-hop crowd

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.